![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | CD19 |
Clinical data | |
Pronunciation | /ˌlɒnkæsˈtʌksɪmæb.ˈtɛsɪriːn/ LON-kas-TUK-si-mab TE-si-reen |
Trade names | Zynlonta |
Other names | ADCT-402, loncastuximab tesirine-lpyl |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
Legal status | |
Legal status | |
Chemical and physical data | |
Formula | C6544H10048N1718O2064S52 |
Molar mass | 147481.45 g·mol−1 |
Loncastuximab tesirine , sold under the brand name Zynlonta, is a medication used to treat large B-cell lymphoma.[1] It is used when other treatments have failed.[1] It is given by injection into a vein.[1]
Common side effects include low platelets, liver inflammation, low white blood cells, low red blood cells, high blood sugar, rash, swelling, and nausea.[1] Other side effects may include infection.[1] Use in pregnancy may harm the baby.[1] It is an antibody-drug conjugate composed of a monoclonal antibody targeting the protein CD19 attached to an alkylating agent.[1]
Loncastuximab tesirine was approved for medical use in the United States in 2021.[1] As of 2022 it is not yet approved in the United Kingdom or Europe.[2] In the United States it costs about 25,500 USD per 10 mg vial as of 2022.[3]
References
edit- ^ a b c d e f g h i "Zynlonta- loncastuximab tesirine injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
- ^ "Loncastuximab tesirine". SPS - Specialist Pharmacy Service. 1 January 2021. Archived from the original on 27 November 2021. Retrieved 30 October 2022.
- ^ "Zynlonta Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 30 October 2022.